BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/13/2017 7:05:00 PM | Browse: 992 | Download: 2241
 |
Received |
|
2016-10-24 10:33 |
 |
Peer-Review Started |
|
2016-10-25 09:19 |
 |
To Make the First Decision |
|
2016-12-02 08:16 |
 |
Return for Revision |
|
2016-12-12 21:55 |
 |
Revised |
|
2016-12-25 23:42 |
 |
Second Decision |
|
2017-01-16 13:58 |
 |
Accepted by Journal Editor-in-Chief |
|
|
 |
Accepted by Executive Editor-in-Chief |
|
2017-01-17 17:01 |
 |
Articles in Press |
|
2017-01-17 17:01 |
 |
Publication Fee Transferred |
|
|
 |
Edit the Manuscript by Language Editor |
|
2017-02-10 16:27 |
 |
Typeset the Manuscript |
|
2017-03-07 09:24 |
 |
Publish the Manuscript Online |
|
2017-03-13 19:06 |
ISSN |
1007-9327 (print) and 2219-2840 (online) |
Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
|
Copyright |
© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
|
Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
Category |
Gastroenterology & Hepatology |
Manuscript Type |
Basic Study |
Article Title |
Therapeutic effect of curcumin on experimental colitis mediated by inhibiting CD8+CD11c+ cells
|
Manuscript Source |
Invited Manuscript |
All Author List |
Hai-Mei Zhao, Fei Han, Rong Xu, Xiao-Ying Huang, Shao-Min Cheng, Min-Fang Huang, Hai-Yang Yue, Xin Wang, Yong Zou, Han-Lin Xu and Duan-Yong Liu |
Funding Agency and Grant Number |
Funding Agency |
Grant Number |
Projects of National Natural Science Foundation of China |
81260595 |
National Natural Science Foundation of China |
81460679 |
Chinese Scholarship Council and Jiangxi Province as visiting scholar |
201408360106 |
Chinese Scholarship Council and Jiangxi Province as visiting scholar |
201408360110 |
Traditional Chinese Medicine project of Health Department of Jiangxi Province |
2015B049 |
Project of Jiangxi University of Traditional Chinese Medicine |
JZYC15S13 |
|
Corresponding Author |
Duan-Yong Liu, Associate Professor, Science and Technology College, Jiangxi University of Traditional Chinese Medicine, 819 Xingwan Road, Nanchang 330004, Jiangxi Province, China. liuduanyong@163.com
|
Key Words |
CD8; CD11c; Curcumin; Experimental colitis; Therapeutic effect |
Core Tip |
CD11c is highly expressed in CD8+ and CD8- dendritic cells (DCs). Overaccumulation of CD8+ DCs is seen in colonic mucosa in experimental colitis and patients with inflammatory bowel disease (IBD). CD8+CD11c+ cells may be a potential strategy to explore the mechanism of action of drugs in IBD. The immunosuppressant curcumin (Cur) plays a therapeutic role in various immune diseases, including IBD and rheumatoid arthritis. However, it is unclear whether Cur regulates level of CD8+CD11c+ cells to treat IBD. We found that the therapeutic effect of Cur in experimental colitis was closely related to decreased levels of CD8+CD11c+ cells. |
Publish Date |
2017-03-13 19:06 |
Citation |
Zhao HM, Han F, Xu R, Huang XY, Cheng SM, Huang MF, Yue HY, Wang X, Zou Y, Xu HL, Liu DY. Therapeutic effect of curcumin on experimental colitis mediated by inhibiting CD8+CD11c+ cells. World J Gastroenterol 2017; 23(10): 1804-1815 |
URL |
http://www.wjgnet.com/1007-9327/full/v23/i10/1804.htm |
DOI |
http://dx.doi.org/10.3748/wjg.v23.i10.1804 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345